Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates

American Journal of Hematology

Volumn 87, Issue 3, 2012, Pages 326-330

  Novelli, Enrico M ^a   Kato, Gregory J ^b   Ragni, Margaret V ^c   Zhang, Yingze ^a   Hildesheim, Mariana E ^a   Nouraie, Mehdi ^d   Barge, Suchitra ^a   Meyer, Michael P ^e   Hassett, Andrea Cortese ^e   Gordeuk, Victor R ^d   Gladwin, Mark T ^a   Isenberg, Jeffrey S ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d HOWARD UNIVERSITY   (United States)

^e ITXM Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; LACTATE DEHYDROGENASE; SILDENAFIL; THROMBOSPONDIN 1;

ACUTE CHEST SYNDROME; ADULT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; STEADY STATE; VASO OCCLUSIVE EVENT;

ACUTE CHEST SYNDROME; ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HEMOGLOBINS; HEMOLYSIS; HUMANS; HYDROXYUREA; L-LACTATE DEHYDROGENASE; LEG ULCER; MALE; MIDDLE AGED; OSTEONECROSIS; PLATELET ACTIVATION; RETROSPECTIVE STUDIES; THROMBOEMBOLISM; THROMBOSPONDIN 1; VASCULAR PATENCY;

EID: 84862810199     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22274     Document Type: Letter

References (25)

1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004; 364: 1343-1360.
2. Hu W, Jin R, Zhang J, et al. The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood 2010; 116: 1613-1622.
3. Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110: 2166-2172.
4. Mohan JS, Lip GY, Bareford D, et al. Platelet P-selectin and platelet mass, volume and component in sickle cell disease: Relationship to genotype. Thromb Res 2006; 117: 623-629.
5. Tomer A, Harker LA, Kasey S, et al. Thrombogenesis in sickle cell disease. J Lab Clin Med 2001; 137: 398-407.
6. Wun T, Paglieroni T, Rangaswami A, et al. Platelet activation in patients with sickle cell disease. Br J Haematol 1998; 100: 741-749.
7. Browne PV, Mosher DF, Steinberg MH, et al. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51: 296-301.
8. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: Potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1626-1631.
9. Antonucci R, Walker R, Herion J, et al. Enhancement of sickle erythrocyte adherence to endothelium by autologous platelets. Am J Hematol 1990; 34: 44-48.
10. Blann AD, Marwah S, Serjeant G, et al. Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity. Blood Coagul Fibrinolysis 2003; 14: 255-259.
11. Brittain HA, Eckman JR, Swerlick RA, et al. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81: 2137-2143.
12. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821.
13. Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA 1974; 71: 1207-1210.
14. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 2008; 65: 713-727.
15. Sugihara K, Sugihara T, Mohandas N, et al. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992; 80: 2634-2642.
16. Hillery CA, Scott JP, Du MC. The carboxy-terminal cell-binding domain of thrombospondin is essential for sickle red blood cell adhesion. Blood 1999; 94: 302-309.
17. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005; 102: 13141-13146.
18. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006; 281: 26069-26080.
19. Williams L, Fu Z, Dulloor P, et al. Identification of Thrombospondin-1 and L-Selectin as Potential Plasma Biomarkers of Silent Cerebral Infarct In Children with Sickle Cell Disease Using a Proteomic-Based Approach in 52nd ASH Annual Meeting and Exposition. 2010: Orlando.
20. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003; 289: 1645-1651.
21. Gordeuk VR, Campbell A, Rana S, et al. Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 2009; 114: 4639-4644.
22. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37-47.
23. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359: 2254-2265.
24. The management of sickle cell disease, NIH guidelines 2002.
25. Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009; 94: 340-347.